about
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphomaPatients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentr
P50
description
researcher ORCID ID = 0000-0003-4448-605X
@en
wetenschapper
@nl
name
Rachel Hamelers
@ast
Rachel Hamelers
@en
Rachel Hamelers
@es
Rachel Hamelers
@nl
type
label
Rachel Hamelers
@ast
Rachel Hamelers
@en
Rachel Hamelers
@es
Rachel Hamelers
@nl
prefLabel
Rachel Hamelers
@ast
Rachel Hamelers
@en
Rachel Hamelers
@es
Rachel Hamelers
@nl
P21
P31
P496
0000-0003-4448-605X